PT  - JOURNAL ARTICLE
AU  - Matthew Gagne
AU  - Juan I. Moliva
AU  - Kathryn E. Foulds
AU  - Shayne F. Andrew
AU  - Barbara J. Flynn
AU  - Anne P. Werner
AU  - Danielle A. Wagner
AU  - I-Ting Teng
AU  - Bob C. Lin
AU  - Christopher Moore
AU  - Nazaire Jean-Baptiste
AU  - Robin Carroll
AU  - Stephanie L. Foster
AU  - Mit Patel
AU  - Madison Ellis
AU  - Venkata-Viswanadh Edara
AU  - Nahara Vargas Maldonado
AU  - Mahnaz Minai
AU  - Lauren McCormick
AU  - Christopher Cole Honeycutt
AU  - Bianca M. Nagata
AU  - Kevin W. Bock
AU  - Caitlyn N. M. Dulan
AU  - Jamilet Cordon
AU  - John-Paul M. Todd
AU  - Elizabeth McCarthy
AU  - Laurent Pessaint
AU  - Alex Van Ry
AU  - Brandon Narvaez
AU  - Daniel Valentin
AU  - Anthony Cook
AU  - Alan Dodson
AU  - Katelyn Steingrebe
AU  - Dillon R. Flebbe
AU  - Saule T. Nurmukhambetova
AU  - Sucheta Godbole
AU  - Amy R. Henry
AU  - Farida Laboune
AU  - Jesmine Roberts-Torres
AU  - Cynthia G. Lorang
AU  - Shivani Amin
AU  - Jessica Trost
AU  - Mursal Naisan
AU  - Manjula Basappa
AU  - Jacquelyn Willis
AU  - Lingshu Wang
AU  - Wei Shi
AU  - Nicole A. Doria-Rose
AU  - Adam S. Olia
AU  - Cuiping Liu
AU  - Darcy R. Harris
AU  - Andrea Carfi
AU  - John R. Mascola
AU  - Peter D. Kwong
AU  - Darin K. Edwards
AU  - Hanne Andersen
AU  - Mark G. Lewis
AU  - Kizzmekia S. Corbett
AU  - Martha C. Nason
AU  - Adrian B. McDermott
AU  - Mehul S. Suthar
AU  - Ian N. Moore
AU  - Mario Roederer
AU  - Nancy J. Sullivan
AU  - Daniel C. Douek
AU  - Robert A. Seder
TI  - mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron
AID  - 10.1101/2022.02.03.479037
DP  - 2022 Jan 01
TA  - bioRxiv
PG  - 2022.02.03.479037
4099  - http://biorxiv.org/content/early/2022/02/04/2022.02.03.479037.short
4100  - http://biorxiv.org/content/early/2022/02/04/2022.02.03.479037.full
AB  - SARS-CoV-2 Omicron is highly transmissible and has substantial resistance to antibody neutralization following immunization with ancestral spike-matched vaccines. It is unclear whether boosting with Omicron-specific vaccines would enhance immunity and protection. Here, nonhuman primates that received mRNA-1273 at weeks 0 and 4 were boosted at week 41 with mRNA-1273 or mRNA-Omicron. Neutralizing antibody titers against D614G were 4760 and 270 reciprocal ID50 at week 6 (peak) and week 41 (pre-boost), respectively, and 320 and 110 for Omicron. Two weeks after boost, titers against D614G and Omicron increased to 5360 and 2980, respectively, for mRNA-1273 and 2670 and 1930 for mRNA-Omicron. Following either boost, 70-80% of spike-specific B cells were cross-reactive against both WA1 and Omicron. Significant and equivalent control of virus replication in lower airways was observed following either boost. Therefore, an Omicron boost may not provide greater immunity or protection compared to a boost with the current mRNA-1273 vaccine.Competing Interest StatementK.S.C. is an inventor on U.S. Patent No. 10,960,070 B2 and International Patent Application No. WO/2018/081318 entitled: Prefusion Coronavirus Spike Proteins and Their Use. K.S.C. is an inventor on U.S. Patent Application No. 62/972,886 entitled: 2019-nCoV Vaccine. L.W., W.S., J.R.M., M.R., N.J.S. and D.C.D are inventors on U.S. Patent Application No. 63/147,419 entitled: Antibodies Targeting the Spike Protein of Coronaviruses. L.P., A.V.R., B.N., D.V., A.C., A.D., K.S., H.A. and M.G.L. are employees of Bioqual. K.S.C, L.W. and W.S. are inventors on multiple U.S. Patent Applications entitled Anti-Coronavirus Antibodies and Methods of Use. A.C. and D.K.E. are employees of Moderna. M.S.S. serves on the scientific board of advisors for Moderna and Ocugen. The other authors declare no competing interests.